Mesoblast Financial Results and Corporate Update Webcast
26 févr. 2023 19h38 HE
|
Mesoblast Limited
NEW YORK, Feb. 26, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss...
Remestemcel-L Clinical and Potency Studies Presented at Premier Meeting of Transplantation Research and Therapy
16 févr. 2023 18h16 HE
|
Mesoblast Limited
NEW YORK, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that two studies on...
FDA Grants Regenerative Medicine Advanced Therapy (Rmat) Designation for Rexlemestrocel-L in Chronic Low Back Pain
08 févr. 2023 18h09 HE
|
Mesoblast Limited
NEW YORK, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the United States...
Mesoblast Resubmits Biologic License Application (BLA) to FDA for Remestemcel-L in Children With Steroid-Refractory Acute Graft Versus Host Disease (Sr-aGVHD)
31 janv. 2023 18h30 HE
|
Mesoblast Limited
Validation of Remestemcel-L Potency Assay used in the Phase 3 Trial which Measures In-Vivo Activity based on Mechanism of Action Assay Identifies High-Potency Product Lots Associated with...
Appendix 4C Quarterly Activity Report
31 janv. 2023 04h40 HE
|
Mesoblast Limited
NEW YORK, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for...
Mesoblast and Oaktree Extend Availability Period of Undrawn Tranches of Financing Facility
22 déc. 2022 19h18 HE
|
Mesoblast Limited
NEW YORK, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that funds managed by...
Children Treated With Remestemcel-L Show Long-Term Survival Through Four Years in Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)
22 nov. 2022 18h32 HE
|
Mesoblast Limited
Key Points: Long-term survival evident through 4 years in children treated with remestemcel-L in Phase 3 trial MSB-GVHD001Overall survival at 2 years was 51% in remestemcel-L treated children and...
Mesoblast Reports Financial Results and Operational Highlights for the Period Ended September 30, 2022
22 nov. 2022 18h01 HE
|
Mesoblast Limited
Durable long-term survival outcomes through 4 years for children with steroid-refractory graft versus host disease (SR-aGVHD) treated with remestemcel-L These long-term survival outcomes are a...
Mesoblast Financial Results and Corporate Update Webcast
21 nov. 2022 06h00 HE
|
Mesoblast Limited
NEW YORK, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss...
Mesoblast Operational and Financial Highlights for Quarter Ended September 30, 2022
30 oct. 2022 19h50 HE
|
Mesoblast Limited
NEW YORK, Oct. 30, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for...